{"id":34696,"date":"2026-01-09T11:05:00","date_gmt":"2026-01-09T16:05:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=34696"},"modified":"2026-10-04T21:37:01","modified_gmt":"2026-10-05T01:37:01","slug":"beyond-the-patent-cliff-15-strategies-for-pharmaceutical-lifecycle-management","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/beyond-the-patent-cliff-15-strategies-for-pharmaceutical-lifecycle-management\/","title":{"rendered":"Beyond the Patent Cliff: 15 Lifecycle Strategies Drugmakers Use to Protect Revenue"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Merck’s Keytruda earned $25 billion in 2023 and $29.5 billion in 2024, and it was the world’s top-selling drug in both years [1]. Its patent exclusivity ends in 2028 [2]. Merck has about two years from now to move sales onto products that biosimilar makers cannot copy on day one.<\/p>\n\n\n\n

That task has a name: lifecycle management. This article describes 15 lifecycle strategies. It sorts them into four classes and tests each one against a documented case. The cases include Humira, Namenda, Soliris, Keytruda, and the ProAir HFA inhaler. Where I calculate a figure, the text labels it as analysis.<\/p>\n\n\n\n

The Short Answer: What Is Pharmaceutical Lifecycle Management?<\/strong><\/h2>\n\n\n\n

Pharmaceutical lifecycle management is the set of legal, regulatory, clinical, and commercial actions that keep a drug’s revenue after its first protection ends. In this article, the term covers actions that extend exclusivity and actions that move patients to a new product. It also covers actions that prepare a company for the price effects of competition.<\/p>\n\n\n\n

What does lifecycle management mean in pharma?<\/strong><\/h3>\n\n\n\n

Lifecycle management starts before approval and continues until the product leaves the market. A team picks the patents to file, the exclusivities to seek, the new forms to develop, and the settlements to accept. Each choice has a legal limit. Courts and the FTC have set several of those limits, and this article shows where.<\/p>\n\n\n\n

What is the difference between a patent and FDA exclusivity?<\/strong><\/h3>\n\n\n\n

The USPTO grants patents. The FDA grants exclusivity when it approves a drug and the statutory requirements are met [4]. Exclusivity can run at the same time as a patent, but it does not have to [4]. The two can expire on different dates, so each needs its own entry in a timeline.<\/p>\n\n\n\n

How long does each type of protection last?<\/strong><\/h3>\n\n\n\n

The table below lists the protection periods that most lifecycle strategies use. The last row is a policy threshold, not an exclusivity.<\/p>\n\n\n\n

Protection<\/th>Length<\/th>Notes<\/th>Source<\/th><\/tr><\/thead>
New chemical entity (NCE) exclusivity<\/td>5 years<\/td>Granted at approval of a new active moiety<\/td>[4]<\/td><\/tr>
Orphan drug exclusivity<\/td>7 years<\/td>For rare diseases<\/td>[4]<\/td><\/tr>
New clinical investigation exclusivity<\/td>3 years<\/td>For a change, if criteria are met<\/td>[4]<\/td><\/tr>
Pediatric exclusivity<\/td>6 months<\/td>Added to existing patents and exclusivity<\/td>[4]<\/td><\/tr>
Patent challenge exclusivity<\/td>180 days<\/td>ANDAs only<\/td>[4]<\/td><\/tr>
Competitive generic therapy exclusivity<\/td>180 days<\/td>ANDAs only<\/td>[26]<\/td><\/tr>
Reference biologic exclusivity<\/td>12 years from first licensure<\/td>Biosimilar application cannot be approved before this date<\/td>[7]<\/td><\/tr>
Patent term extension<\/td>Up to 5 years<\/td>Total term after approval cannot exceed 14 years<\/td>[6]<\/td><\/tr>
Medicare negotiation eligibility<\/td>9 years (small molecule), 13 years (biologic)<\/td>Policy threshold under the Inflation Reduction Act<\/td>[8]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What the Data Shows: Five Findings That Matter<\/strong><\/h2>\n\n\n\n

These five findings can be quoted without the rest of the article. Each one names its source. Items marked “Analysis” are my own calculations from the cited figures.<\/p>\n\n\n\n

    \n
  1. AbbVie’s Humira composition patent (US 6,090,382) expired in December 2016 [10]. The first US biosimilar, Amgen’s Amjevita, launched on January 31, 2023 [3]. Analysis: the gap is about six years.<\/li>\n\n\n\n
  2. Keytruda Qlex is approved for 38 of the 41 solid tumor indications of intravenous Keytruda [2]. Analysis: that is 92.7% of the indications.<\/li>\n\n\n\n
  3. Alexion reported that it had converted 70% of Soliris patients to Ultomiris [14]. Amgen’s Soliris biosimilar launched in March 2025 [13].<\/li>\n\n\n\n
  4. Soliris biosimilars launched at wholesale prices about 10% and 30% below Soliris [15]. Amjevita launched at a wholesale price 55% below the Humira list price [16].<\/li>\n\n\n\n
  5. Teva listed nine patents for ProAir HFA [18]. The Federal Circuit affirmed delisting of five device patents on December 20, 2024 [17]. Analysis: five of nine is 56%.<\/li>\n<\/ol>\n\n\n\n
    \n

    Over more than 20 years, Humira “has brought in $200 billion in total sales,” according to AJMC [3].<\/p>\n<\/blockquote>\n\n\n\n

    Methodology and Limits of This Analysis<\/strong><\/h2>\n\n\n\n

    What data did I analyze?<\/strong><\/h3>\n\n\n\n

    I used public documents and published reports. These include FDA reference pages, federal statutes, court decision summaries, company announcements as reported by trade press, and law firm analyses. I retrieved them in October 2026. This article does not reproduce raw Orange Book, Purple Book, or USPTO record pulls. Check each date in those databases before you rely on it.<\/p>\n\n\n\n

    How did I calculate derived figures?<\/strong><\/h3>\n\n\n\n

    I used simple arithmetic on reported figures. Percentage discounts are the price difference divided by the Soliris price. Revenue growth is the later figure divided by the earlier figure. Time gaps count from the month of the first event to the month of the second. I label each result as analysis.<\/p>\n\n\n\n

    What are the limits?<\/strong><\/h3>\n\n\n\n

    Four limits apply. First, I included a case only if I could find a source for its key facts. Second, patent counts differ by source and by counting method. Third, some reports are from 2025, and later events may have changed the status of disputes. Fourth, the article describes legal concepts for business planning. It is not legal advice.<\/p>\n\n\n\n

    A Taxonomy of 15 Lifecycle Strategies<\/strong><\/h2>\n\n\n\n

    This classification is my own. It is not an established industry standard. It has four classes. Class A protects the core asset. Class B adds new regulatory rights. Class C moves patients to a new form or product. Class D adapts to market and policy change.<\/p>\n\n\n\n

    #<\/th>Strategy<\/th>Class<\/th>Documented example<\/th>Source<\/th><\/tr><\/thead>
    1<\/td>Layer secondary patents<\/td>A<\/td>Humira<\/td>[10][12]<\/td><\/tr>
    2<\/td>Settle for fixed entry dates<\/td>A<\/td>Humira, Soliris<\/td>[11][13]<\/td><\/tr>
    3<\/td>Restore patent term<\/td>A<\/td>Statutory tool; Keytruda timeline<\/td>[6][2]<\/td><\/tr>
    4<\/td>Add pediatric exclusivity<\/td>A<\/td>Statutory tool<\/td>[4][26]<\/td><\/tr>
    5<\/td>Earn new clinical investigation exclusivity<\/td>B<\/td>Statutory tool<\/td>[4][5]<\/td><\/tr>
    6<\/td>Start with an orphan indication<\/td>B<\/td>Statutory tool<\/td>[4][8]<\/td><\/tr>
    7<\/td>Expand indications<\/td>B<\/td>Keytruda, Farxiga<\/td>[2][9]<\/td><\/tr>
    8<\/td>Reformulate<\/td>C<\/td>Namenda XR<\/td>[23][24]<\/td><\/tr>
    9<\/td>Change the route of administration<\/td>C<\/td>Keytruda Qlex<\/td>[2][21]<\/td><\/tr>
    10<\/td>Secure delivery-platform rights<\/td>C<\/td>Merck and Halozyme<\/td>[20]<\/td><\/tr>
    11<\/td>Move patients to a successor molecule<\/td>C<\/td>Soliris to Ultomiris<\/td>[14]<\/td><\/tr>
    12<\/td>Keep Orange Book listings clean<\/td>D<\/td>ProAir HFA<\/td>[17][18]<\/td><\/tr>
    13<\/td>Model biosimilar discount tiers<\/td>D<\/td>Amjevita, Bkemv, Epysqli<\/td>[15][16][27]<\/td><\/tr>
    14<\/td>Plan around the Medicare negotiation clock<\/td>D<\/td>Farxiga<\/td>[8][9]<\/td><\/tr>
    15<\/td>Reset the cost base before loss of exclusivity<\/td>D<\/td>Merck<\/td>[20]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Class A: Protect the Core Asset (Strategies 1 to 4)<\/strong><\/h2>\n\n\n\n

    Strategy 1: How do drugmakers layer secondary patents?<\/strong><\/h3>\n\n\n\n

    A company files patents on formulations, manufacturing methods, and uses after it files the composition patent. Each patent expires on its own date. Together they can hold a competitor back after the main patent ends.<\/p>\n\n\n\n

    How many patents protected Humira?<\/strong><\/h4>\n\n\n\n

    A Sherman Act antitrust suit against AbbVie referred to 132 patents on Humira [12]. In the BPCIA litigation with Amgen, AbbVie sued on 10 patents in the first wave and identified 51 more for a second wave [10]. Analysis: that is 61 patents that AbbVie asserted or named against one biosimilar maker.<\/p>\n\n\n\n

    What happened after the composition patent expired?<\/strong><\/h4>\n\n\n\n

    The composition patent expired in December 2016 [10]. The FDA approved Amjevita in September 2016 [11]. AbbVie said its other patents expire no earlier than 2022 [11]. Amgen launched on January 31, 2023 [3]. Analysis: Amjevita reached the US market about six years and four months after approval.<\/p>\n\n\n\n

    The layers did not set the launch date by themselves. A settlement did, as the next strategy shows.<\/p>\n\n\n\n

    Strategy 2: Why do brand companies settle for fixed entry dates?<\/strong><\/h3>\n\n\n\n

    A settlement replaces litigation risk with a known date. On September 28, 2017, AbbVie and Amgen ended all Humira patent litigation [11]. The settlement set the EU launch for October 16, 2018 and the US launch for January 31, 2023 [11].<\/p>\n\n\n\n

    Amgen’s deal gave it six months on the market before other adalimumab biosimilars could launch [3]. Six more products were expected in July 2023, and Sandoz’s Hyrimoz in September [3].<\/p>\n\n\n\n

    Alexion used the same tool for Soliris. It settled with Amgen in May 2020 and allowed a US launch from March 1, 2025 [13].<\/p>\n\n\n\n

    What did the Amgen settlements set?<\/strong><\/h4>\n\n\n\n

    Each settlement fixed a launch date years ahead. Humira’s date was 63 months after the settlement (September 2017 to January 2023). Soliris’s date was about 58 months after its settlement (May 2020 to March 2025). Both figures are analysis.<\/p>\n\n\n\n

    What limits do antitrust rules put on settlements?<\/strong><\/h4>\n\n\n\n

    In FTC v. Actavis (2013), the US Supreme Court held that reverse-payment patent settlements are not presumptively unlawful. Courts review them under the rule of reason [25]. A settlement that pays a generic maker to stay out can create antitrust risk. A settlement that sets only an entry date has less risk.<\/p>\n\n\n\n

    Strategy 3: How does patent term extension work?<\/strong><\/h3>\n\n\n\n

    Under 35 U.S.C. section 156, a company can extend one patent to recover time lost during FDA review. The extension cannot exceed five years. The total patent term after approval cannot exceed 14 years [6].<\/p>\n\n\n\n

    Keytruda shows the arithmetic. The intravenous product has been on the market since 2014 [2]. Its patent exclusivity ends in 2028 [2]. Analysis: 2028 minus 2014 is 14 years, which equals the statutory cap. The sources I reviewed do not say which patent produces the 2028 date, so this match is an observation and not a finding.<\/p>\n\n\n\n

    Strategy 4: How does pediatric exclusivity add six months?<\/strong><\/h3>\n\n\n\n

    When a sponsor earns pediatric exclusivity, FDA adds six months to all existing patents and exclusivity for that active moiety [26]. It does not stand alone. It attaches to protection that already exists [26]. It runs from the end of the other protection and is not a patent extension [5].<\/p>\n\n\n\n

    The benefit is small per drug and large for a product with high sales. Six months of a blockbuster is a large amount of revenue.<\/p>\n\n\n\n

    Class B: Add New Regulatory Rights (Strategies 5 to 7)<\/strong><\/h2>\n\n\n\n

    Strategy 5: Can a new indication or form earn its own exclusivity?<\/strong><\/h3>\n\n\n\n

    Yes, in some cases. A supplement to a new drug application can receive three years of exclusivity [5]. FDA describes this as exclusivity for a change, if criteria are met [4]. The protection covers the change. It does not cover the whole drug.<\/p>\n\n\n\n

    Strategy 6: Why start with an orphan indication?<\/strong><\/h3>\n\n\n\n

    Orphan drug exclusivity lasts seven years [4]. It also affects policy timing. Medicare negotiation exempts a drug if its only FDA-approved indication has an orphan designation [8]. The exemption depends on orphan being the only approved indication. A company that adds a non-orphan indication gives up that exemption.<\/p>\n\n\n\n

    Strategy 7: Does expanding indications extend a drug’s life?<\/strong><\/h3>\n\n\n\n

    It extends revenue, not legal protection. Keytruda has been on the market since 2014 and is approved for 41 solid tumor indications [2]. Each indication adds patients.<\/p>\n\n\n\n

    New indications do not reset the Medicare negotiation clock. Farxiga was approved for type 2 diabetes in 2014 and for heart failure in 2019, and the second approval did not restart its timeline [9].<\/p>\n\n\n\n

    Class C: Shift Patients to a New Form or Product (Strategies 8 to 11)<\/strong><\/h2>\n\n\n\n

    Strategy 8: When does a reformulation become product hopping?<\/strong><\/h3>\n\n\n\n

    A reformulation is a new version of the same drug, such as an extended-release tablet. Product hopping is the practice of moving patients to the new version before generics of the old version arrive.<\/p>\n\n\n\n

    What did Actavis do with Namenda?<\/strong><\/h4>\n\n\n\n

    Namenda IR was a twice-daily memantine tablet and a best seller with $1.5 billion in sales [23]. Its patent was set to expire in July 2015 [24]. Actavis launched Namenda XR, a once-daily capsule, and then announced it would stop making IR [24]. New York sued under the Sherman Act [23].<\/p>\n\n\n\n

    What did the Second Circuit decide?<\/strong><\/h4>\n\n\n\n

    In New York v. Actavis, 787 F.3d 638 (2d Cir. 2015), the court upheld an injunction. The injunction required Actavis to keep Namenda IR on the market until generics arrived [23]. A summary in the AMA Journal of Ethics reads the decision as a bar on product hopping that is coercive and restricts competition [24].<\/p>\n\n\n\n

    The lesson is narrow. A company may launch a better version. It cannot remove the old version to force patients to switch before generics enter.<\/p>\n\n\n\n

    Strategy 9: How does a new route of administration protect a drug?<\/strong><\/h3>\n\n\n\n

    Merck’s Keytruda Qlex is the current example. It combines pembrolizumab with berahyaluronidase alfa, an enzyme that increases absorption under the skin [2].<\/p>\n\n\n\n

    What did the FDA approve?<\/strong><\/h4>\n\n\n\n

    The FDA approved Keytruda Qlex in September 2025 for adults and for children aged 12 and older [21]. It is approved for 38 of the 41 solid tumor indications of intravenous Keytruda [2]. The approval rested on an open-label trial of 377 patients with newly diagnosed metastatic non-small cell lung cancer [2]. The Medical Letter calls it the first immune checkpoint inhibitor that patients can receive subcutaneously in the US [2]. Roche’s Tecentriq and Bristol Myers Squibb’s Opdivo had already received subcutaneous approvals within the prior year [21].<\/p>\n\n\n\n

    How much Keytruda volume can move to Qlex?<\/strong><\/h4>\n\n\n\n

    Merck expects to switch 30% to 40% of Keytruda uses to the subcutaneous version in about 18 months to two years [20]. Merck priced Qlex at parity with the intravenous product [1]. A three-week course of intravenous Keytruda costs almost $11,800 [1].<\/p>\n\n\n\n

    Analysts see limits. A GlobalData consultant noted that combination agents such as chemotherapies and antibody-drug conjugates need intravenous administration [22]. Another analyst expects a sales drop after the intravenous exclusivity ends, even with Qlex [22].<\/p>\n\n\n\n

    Strategy 10: Why secure delivery-platform rights early?<\/strong><\/h3>\n\n\n\n

    A new route often depends on a third party’s technology. Merck’s subcutaneous product depends on a human hyaluronidase protein. Merck faces ongoing patent litigation with Halozyme over that protein [20]. The US Patent and Trademark Office issued a post-grant review on a Merck challenge to some Halozyme patents [20]. This status is from September 2025 reporting, so check current dockets.<\/p>\n\n\n\n

    The strategy is to settle platform rights before the product depends on them. A lifecycle product that carries a new patent dispute can lose the value it was built to protect.<\/p>\n\n\n\n

    Strategy 11: How does a successor molecule protect revenue?<\/strong><\/h3>\n\n\n\n

    A successor molecule is a newer drug in the same franchise. Alexion’s Ultomiris (ravulizumab) won FDA approval in 2018 [14]. In its second-quarter 2020 results, Alexion said it had converted 70% of Soliris patients to Ultomiris [14].<\/p>\n\n\n\n

    What did the sales numbers show?<\/strong><\/h4>\n\n\n\n

    Soliris net sales were $975.5 million in that quarter, against $980.8 million a year earlier [14]. Ultomiris sales were $251.1 million, against $54.2 million [14]. Analysis: combined sales rose from $1,035.0 million to $1,226.6 million, which is 18.5% growth. Ultomiris went from 5.2% to 20.5% of the combined total.<\/p>\n\n\n\n

    What happened when Soliris biosimilars arrived?<\/strong><\/h4>\n\n\n\n

    Amgen’s Bkemv launched in March 2025 as the first interchangeable biosimilar to Soliris [13]. Teva and Samsung Bioepis launched Epysqli on April 7, 2025 [27]. Alexion had moved most patients to its own successor about five years before the first launch. Analysis: the five-year gap runs from the 2020 results to the March 2025 launch.<\/p>\n\n\n\n

    Class D: Adapt to Market and Policy Change (Strategies 12 to 15)<\/strong><\/h2>\n\n\n\n

    Strategy 12: How do Orange Book listing rules affect lifecycle plans?<\/strong><\/h3>\n\n\n\n

    The Orange Book lists patents that claim a drug or a method of using it [4]. A listed patent can trigger a 30-month stay when a generic maker files a Paragraph IV certification. The Federal Circuit has said this stay may give “significant incentives to improperly list patents” [19].<\/p>\n\n\n\n

    What did Teva v. Amneal decide?<\/strong><\/h4>\n\n\n\n

    Teva listed nine patents for its ProAir HFA albuterol inhaler [18]. Teva asserted five of them against Amneal [18]. The five patents claimed inhaler components such as a dose counter and canister. None recited the active ingredient, albuterol sulfate [17]. On December 20, 2024, the Federal Circuit affirmed an order to delist them [17].<\/p>\n\n\n\n

    The rule is clear. A device patent that does not claim the drug is not properly listed. A lifecycle plan that counts on such a listing for a 30-month stay is at risk.<\/p>\n\n\n\n

    Strategy 13: How should you model biosimilar discount tiers?<\/strong><\/h3>\n\n\n\n

    Biosimilar makers launch with more than one price. Amgen offered Amjevita at two levels: a wholesale price 55% below Humira’s list price, and a list price 5% below it [16]. The two prices were $1,557 and $3,288 per 40 mg pen [16]. Analysis: both imply a Humira list price of about $3,460 per pen.<\/p>\n\n\n\n

    Soliris biosimilars used a similar range. Soliris had a wholesale price of $6,523 per vial [15]. Bkemv’s was more than $5,870, about 10% below [15]. Epysqli’s was $4,566, which is 30% below [15].<\/p>\n\n\n\n

    Analysis: across the four price points in these cases, discounts range from 5% to 55%. A forecast that assumes one discount level will miss some of that range.<\/p>\n\n\n\n

    Strategy 14: How does the Medicare negotiation clock change planning?<\/strong><\/h3>\n\n\n\n

    The Inflation Reduction Act makes some drugs eligible for Medicare price negotiation. A small-molecule drug is eligible nine years after approval. A biologic is eligible after 13 years [8]. New indications or formulations do not change that date, and the negotiated price applies to all dosage forms and strengths [9].<\/p>\n\n\n\n

    Several drugs are exempt. They include drugs with a marketed generic or biosimilar, orphan-only drugs, and plasma-derived products [8]. Drugs with 2021 Medicare spending under $200 million are also exempt [8]. An unbranded version from the same manufacturer does not prevent selection [9]. CMS scheduled the first negotiated prices to take effect on January 1, 2026 [8].<\/p>\n\n\n\n

    For lifecycle planning, the effect is to shorten the value of late-life product changes. A new formulation does not buy a new negotiation clock.<\/p>\n\n\n\n

    Strategy 15: Why reset the cost base before loss of exclusivity?<\/strong><\/h3>\n\n\n\n

    Merck launched a cost program to save $3 billion a year by the end of 2027 [20]. The plan cuts about 6,000 jobs, or 8% of its workforce [20]. Fierce Pharma links the program to Keytruda’s expected patent expiration and weak Gardasil sales [20].<\/p>\n\n\n\n

    The strategy accepts that some revenue will fall. It cuts costs before the fall, not after.<\/p>\n\n\n\n

    Keytruda Patent Expiration: What Merck Is Doing Before 2028<\/strong><\/h2>\n\n\n\n

    What is the Keytruda patent clock?<\/strong><\/h3>\n\n\n\n

    Keytruda reached the market in 2014 [2]. Patent exclusivity for the intravenous product ends in 2028 [2]. Sales reached $29.5 billion in 2024, which is 18% above 2023’s $25 billion [1]. The 18% is my calculation.<\/p>\n\n\n\n

    Which of the 15 strategies is Merck using?<\/strong><\/h3>\n\n\n\n

    Merck uses at least four. It has expanded indications (Strategy 7) to 41 solid tumor indications [2]. It has changed the route of administration (Strategy 9) with Qlex [2]. It is defending platform rights (Strategy 10) in the Halozyme dispute [20]. It has begun a cost reset (Strategy 15) [20].<\/p>\n\n\n\n

    What happens next for Keytruda? (Forecast, not fact)<\/strong><\/h3>\n\n\n\n

    Analysts quoted in the sources expect Merck to hold higher sales for longer with Qlex but to still see a drop after intravenous exclusivity ends [22]. These are expectations. They are not confirmed events. The sources I reviewed do not say whether the 2028 date applies equally to Qlex, so check the Orange Book and Purple Book entries and any biosimilar filings.<\/p>\n\n\n\n

    Scenario Analysis: What If Qlex Moves 30% to 40% of Keytruda Use?<\/strong><\/h2>\n\n\n\n

    This is an illustration, not a forecast. It uses three assumptions. First, 2024 sales of $29.5 billion are the base [1]. Second, Merck’s 30% to 40% target applies to revenue as well as to uses [20]. Third, Qlex sells at price parity [1].<\/p>\n\n\n\n

    Analysis: 30% of $29.5 billion is $8.85 billion. 40% is $11.8 billion. That is the range of annual revenue that would sit in the subcutaneous product under those assumptions.<\/p>\n\n\n\n

    The assumptions are weak in two places. Combination regimens that need intravenous drugs may limit the switch [22]. The sources also do not say how much of the Qlex revenue stays protected after 2028. Treat the range as a way to frame the question, not as a prediction.<\/p>\n\n\n\n

    What This Means for Brand Manufacturers, Generic Makers, and Biosimilar Developers<\/strong><\/h2>\n\n\n\n

    What this means for brand manufacturers<\/strong><\/h3>\n\n\n\n

    Patent layers alone did not set Humira’s entry date. Settlements did [11]. A brand team should plan for the settlement date as well as the last patent date. The Namenda case shows the limit on forced switching [23]. The ProAir case shows the limit on device patent listings [17].<\/p>\n\n\n\n

    What this means for generic entry<\/strong><\/h3>\n\n\n\n

    A generic maker can challenge an Orange Book listing as well as a patent. Teva v. Amneal gives a clear test: the listed patent must claim the drug [17]. Generic makers can also ask whether a brand’s 30-month stay rests on a patent that fails that test.<\/p>\n\n\n\n

    What this means for biosimilars<\/strong><\/h3>\n\n\n\n

    Biosimilar makers launched into negotiated windows in the cases above. Amgen had six months alone on the Humira market [3]. Interchangeability can set a product apart, as Bkemv did when it launched as the first interchangeable Soliris biosimilar [13]. Price tiers matter, and Soliris biosimilars used discounts of about 10% and 30% [15].<\/p>\n\n\n\n

    How DrugPatentWatch Data Fits Into Lifecycle Planning<\/strong><\/h2>\n\n\n\n

    Which records should you check for each strategy?<\/strong><\/h3>\n\n\n\n

    DrugPatentWatch is a database that gathers patent, exclusivity, and litigation records for drug products in one place [28]. Analysts can use it to find the expiry dates and exclusivity codes that these strategies depend on. It does not replace primary evidence. Confirm each date against the FDA Orange Book, the Purple Book, and the court docket [4].<\/p>\n\n\n\n

    A practical check list has four items. First, list each patent and its expiry date. Second, list each FDA exclusivity and its end date. Third, list open Paragraph IV or BPCIA disputes. Fourth, compare the result with settlement dates, which public databases often do not show.<\/p>\n\n\n\n

    Key Takeaways<\/strong><\/h2>\n\n\n\n
      \n
    • Keytruda earned $29.5 billion in 2024, and its patent exclusivity ends in 2028 [1][2].<\/li>\n\n\n\n
    • Humira’s composition patent expired in December 2016, and the first US biosimilar launched on January 31, 2023 [10][3].<\/li>\n\n\n\n
    • Settlements set the entry dates for Humira and Soliris biosimilars [11][13].<\/li>\n\n\n\n
    • A court barred a forced switch from Namenda IR to XR before generics arrived [23].<\/li>\n\n\n\n
    • Keytruda Qlex covers 38 of 41 solid tumor indications of the intravenous product [2].<\/li>\n\n\n\n
    • Alexion moved 70% of Soliris patients to Ultomiris before biosimilars arrived [14].<\/li>\n\n\n\n
    • The Federal Circuit held that device patents that do not claim the drug are not properly listed in the Orange Book [17].<\/li>\n\n\n\n
    • Biosimilar discounts in these cases ranged from 5% to 55% [15][16].<\/li>\n\n\n\n
    • New indications and formulations do not reset the Medicare negotiation clock [9].<\/li>\n<\/ul>\n\n\n\n

      FAQ<\/strong><\/h2>\n\n\n\n

      What is the difference between a patent and FDA exclusivity?<\/strong><\/h3>\n\n\n\n

      A patent comes from the USPTO. Exclusivity comes from the FDA at approval. Exclusivity may run at the same time as a patent, but it does not have to [4].<\/p>\n\n\n\n

      How does pediatric exclusivity appear in the Orange Book?<\/strong><\/h3>\n\n\n\n

      The Orange Book lists the patent twice. One entry shows the original expiry date. A second shows the date with the six months added [26].<\/p>\n\n\n\n

      Which drugs are exempt from Medicare price negotiation?<\/strong><\/h3>\n\n\n\n

      Exempt drugs include those with a marketed generic or biosimilar. They also include orphan-only drugs, plasma-derived products, and drugs below the Medicare spending floor [8].<\/p>\n\n\n\n

      Who gets 180-day exclusivity?<\/strong><\/h3>\n\n\n\n

      FDA grants 180-day patent challenge exclusivity to ANDAs, and it grants a separate 180-day competitive generic therapy exclusivity to ANDAs [26][4]. Both apply to generic applications, not to brand products.<\/p>\n\n\n\n

      Does interchangeability matter for lifecycle planning?<\/strong><\/h3>\n\n\n\n

      Yes. An interchangeable biosimilar can allow pharmacist substitution without a call to the prescriber, subject to state law [3]. Bkemv launched as the first interchangeable Soliris biosimilar [13]. Amjevita launched without an interchangeability designation [16].<\/p>\n\n\n\n

      How many Humira biosimilars launched in 2023?<\/strong><\/h3>\n\n\n\n

      At least seven were expected [3]. Amjevita launched in January. Six more were expected in July and Hyrimoz in September [3].<\/p>\n\n\n\n

      Do European courts always grant brand-company injunctions?<\/strong><\/h3>\n\n\n\n

      No. The Unified Patent Court refused preliminary injunctions against Amgen’s and Samsung Bioepis’s eculizumab biosimilars in mid-2024. Its Court of Appeal refused again in December 2024 [13].<\/p>\n\n\n\n

      How much have biosimilars saved?<\/strong><\/h3>\n\n\n\n

      The Vizient 2022 Biosimilar Survey found biosimilars saved $12.6 billion between 2014 and 2022 [29].<\/p>\n\n\n\n

      Does an unbranded version stop Medicare negotiation?<\/strong><\/h3>\n\n\n\n

      No. An unbranded drug that the primary manufacturer offers does not prevent a drug from being selected [9].<\/p>\n\n\n\n

      Why is the biologic exclusivity period 12 years if Medicare uses 13?<\/strong><\/h3>\n\n\n\n

      They are separate rules with separate purposes. FDA cannot approve a biosimilar until 12 years after the reference product’s first licensure [7]. Medicare negotiation eligibility for biologics begins after 13 years [8]. Analysis: the two dates are one year apart.<\/p>\n\n\n\n

      References<\/strong><\/h2>\n\n\n\n
        \n
      1. PharmaLive. (2025). As exclusivity loss looms, Merck wins subcutaneous approval for Keytruda. https:\/\/www.pharmalive.com\/as-exclusivity-loss-looms-merck-wins-subcutaneous-approval-for-keytruda\/<\/li>\n\n\n\n
      2. The Medical Letter. (2025, November 10). In brief: Keytruda Qlex, a subcutaneous formulation of pembrolizumab. The Medical Letter on Drugs and Therapeutics, 67(1741), e184. https:\/\/doi.org\/10.58347\/tml.2025.1741f<\/li>\n\n\n\n
      3. AJMC. (2023, January 31). First Humira biosimilar, Amjevita, launches in the United States. https:\/\/ajmc.com\/view\/first-humira-biosimilar-amjevita-launches-in-the-united-states<\/li>\n\n\n\n
      4. U.S. Food and Drug Administration. (n.d.). How can I better understand patents and exclusivity? https:\/\/www.fda.gov\/industry\/fda-basics-industry\/how-can-i-better-understand-patents-and-exclusivity<\/li>\n\n\n\n
      5. U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions for new drug product exclusivity. https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/smallbusinessassistance\/ucm069962.htm<\/li>\n\n\n\n
      6. 35 U.S.C. section 156. Extension of patent term. Legal Information Institute, Cornell Law School. https:\/\/www.law.cornell.edu\/uscode\/text\/35\/156<\/li>\n\n\n\n
      7. 42 U.S.C. section 262(k)(7). Licensure of biological products as biosimilar or interchangeable. Legal Information Institute, Cornell Law School. https:\/\/www.law.cornell.edu\/uscode\/text\/42\/262<\/li>\n\n\n\n
      8. Morrison & Foerster. (2023, January 20). CMS reveals new details on Medicare drug price negotiation program. https:\/\/lifesciences.mofo.com\/topics\/cms-reveals-new-details-on-medicare-drug-price-negotiation-program<\/li>\n\n\n\n
      9. Milliman. (n.d.). Medicare price negotiation: A paradigm shift in Part D access and cost. https:\/\/milliman.com\/en\/insight\/medicare-price-negotiation-paradigm-shiftpart-d-access-cost<\/li>\n\n\n\n
      10. Clarivate. (n.d.). [Analysis of AbbVie’s U.S. Humira patent defense and adalimumab biosimilar settlements]. https:\/\/clarivate.com\/?p=251284<\/li>\n\n\n\n
      11. GaBI Online. (2017). Amgen’s adalimumab biosimilar will only be launched in US in 2023. https:\/\/gabionline.net\/layout\/set\/print\/biosimilars\/news\/Amgen-s-adalimumab-biosimilar-will-only-be-launched-in-US-in-2023<\/li>\n\n\n\n
      12. BioWorld. (n.d.). Biosimilar topic archive [entry on the Sherman Act suit over 132 Humira patents]. https:\/\/www.bioworld.com\/articles\/topic\/272?page=14<\/li>\n\n\n\n
      13. Pearce IP. (2025, March 5). Amgen launches first US eculizumab biosimilar with interchangeability. https:\/\/www.pearceip.law\/?p=53980<\/li>\n\n\n\n
      14. Center for Biosimilars. (n.d.). Alexion offloads market share from Soliris. https:\/\/www.centerforbiosimilars.com\/news\/alexion-offloads-market-share-from-soliris<\/li>\n\n\n\n
      15. AIS Health. (2025, April 10). News briefs: Two Soliris biosimilars are now available. https:\/\/aishealth.mmitnetwork.com\/blogs\/radar-on-specialty-pharmacy\/news-briefs-two-soliris-biosimilars-are-now-available<\/li>\n\n\n\n
      16. Pharma Manufacturing. (2023, January 31). Amgen launches first Humira biosimilar in U.S. https:\/\/pharmamanufacturing.com\/21546256<\/li>\n\n\n\n
      17. Cooley. (2025, January 2). Teva v. Amneal ruling interprets Orange Book listing statute, affirms delisting of device patents. https:\/\/www.cooley.com\/news\/insight\/2025\/2025-01-02-teva-v-amneal-ruling-interprets-orange-book-listing-statute-affirms-delisting-of-device-patents<\/li>\n\n\n\n
      18. Polsinelli. (2024). Federal Circuit decides case involving Orange Book listing of device patents. https:\/\/www.polsinelli.com\/publications\/federal-circuit-decides-case-involving-orange-book-listing-of-device-patents<\/li>\n\n\n\n
      19. Crowell & Moring. (n.d.). Only drugs allowed: Federal Circuit affirms order to delist device patents from the Orange Book. https:\/\/crowell.com\/en\/insights\/client-alerts\/only-drugs-allowed-federal-circuit-affirms-order-to-delist-device-patents-from-the-orange-book<\/li>\n\n\n\n
      20. Fierce Pharma. (2025). Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection. https:\/\/fiercepharma.com\/pharma\/merck-scores-fda-approval-subcutaneous-keytruda<\/li>\n\n\n\n
      21. MedCity News. (2025, September). Merck’s injectable version of blockbuster cancer drug Keytruda wins FDA approval. https:\/\/medcitynews.com\/2025\/09\/mercks-injectable-version-of-blockbuster-cancer-drug-keytruda-wins-fda-approval\/<\/li>\n\n\n\n
      22. Pharmaceutical Technology. (2025). MSD wins SC Keytruda approval, but analysts sceptical on impact. https:\/\/www.pharmaceutical-technology.com\/news\/msd-keytruda-qlex-subcutaenous-fda-approval\/<\/li>\n\n\n\n
      23. New York ex rel. Schneiderman v. Actavis PLC, 787 F.3d 638 (2d Cir. 2015). Case summary: Quimbee. https:\/\/www.quimbee.com\/cases\/new-york-ex-rel-schneiderman-v-actavis-plc<\/li>\n\n\n\n
      24. AMA Journal of Ethics. (2015, August). A legal test for the pharmaceutical company practice of “product hopping.” https:\/\/journalofethics.ama-assn.org\/article\/legal-test-pharmaceutical-company-practice-product-hopping\/2015-08<\/li>\n\n\n\n
      25. Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013). https:\/\/www.supremecourt.gov\/opinions\/12pdf\/12-416_m5n0.pdf<\/li>\n\n\n\n
      26. U.S. Food and Drug Administration. (n.d.). Frequently asked questions on patents and exclusivity. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/ucm079031.htm<\/li>\n\n\n\n
      27. Pearce IP. (2025, April 7). Teva\/Samsung Bioepis launch Epysqli (eculizumab-aagh) in US. https:\/\/www.pearceip.law\/2025\/04\/07\/teva-samsung-bioepis-launch-epysqli-eculizumab-aagh-in-us\/<\/li>\n\n\n\n
      28. DrugPatentWatch. (n.d.). DrugPatentWatch. https:\/\/www.drugpatentwatch.com\/<\/li>\n\n\n\n
      29. TechTarget. (2023). AbbVie faces competitor as a new Humira biosimilar comes to market. https:\/\/www.techtarget.com\/pharmalifesciences\/news\/366606528\/Abbvie-Faces-Competitor-as-a-New-Humira-Biosimilar-Comes-to-Market<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

        Merck’s Keytruda earned $25 billion in 2023 and $29.5 billion in 2024, and it was the world’s top-selling drug in […]<\/p>\n","protected":false},"author":1,"featured_media":39778,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-34696","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=34696"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34696\/revisions"}],"predecessor-version":[{"id":39779,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/34696\/revisions\/39779"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39778"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=34696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=34696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=34696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}